U.S. Markets close in 5 hrs 23 mins
  • S&P 500

    3,891.88
    -33.55 (-0.85%)
     
  • Dow 30

    31,779.89
    -181.97 (-0.57%)
     
  • Nasdaq

    13,432.67
    -165.29 (-1.22%)
     
  • Russell 2000

    2,277.11
    -7.27 (-0.32%)
     
  • Crude Oil

    62.90
    -0.32 (-0.51%)
     
  • Gold

    1,773.10
    -24.80 (-1.38%)
     
  • Silver

    27.82
    -0.11 (-0.40%)
     
  • EUR/USD

    1.2222
    +0.0054 (+0.4400%)
     
  • 10-Yr Bond

    1.4560
    +0.0670 (+4.82%)
     
  • Vix

    22.43
    +1.09 (+5.11%)
     
  • GBP/USD

    1.4153
    +0.0012 (+0.0863%)
     
  • USD/JPY

    106.1830
    +0.3010 (+0.2843%)
     
  • BTC-USD

    50,988.55
    +1,477.27 (+2.98%)
     
  • CMC Crypto 200

    1,019.86
    +25.19 (+2.53%)
     
  • FTSE 100

    6,682.35
    +23.38 (+0.35%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference

  • Oops!
    Something went wrong.
    Please try again later.
Solid Biosciences Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Jennifer Ziolkowski, Chief Financial Officer, Joel Schneider, Chief Technology Officer and Cathryn Clary, Interim Chief Medical Officer, will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Tuesday, October 6, 2020 at 4:45 pm ET.

A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for approximately 30 days on the Events page.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com